Andreas is leading the company’s global efforts to support pipeline progression by applying the latest advances in data science, machine learning and artificial intelligence on translationally relevant data sets. Dr. Raue brings more than 10 years of experience in computational science, as well as several years of industry leadership experience in immune-oncology antibody development at Merrimack Pharmaceuticals. Andreas received his PhD in theoretical physics from the University of Freiburg where he applied computational modeling and analysis to biological and medical problems. His research has been published in various scientific journals and presented at international conference. Dr. Raue is inspired by the potential of leveraging innovative single-cell technologies and machine learning for the advancement of cancer research.